Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Calidi Biotherapeutics Inc. (CLDI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: CLDI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -56.44% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 24.64M USD | Price to earnings Ratio - | 1Y Target Price 6.25 |
Price to earnings Ratio - | 1Y Target Price 6.25 | ||
Volume (30-day avg) 629952 | Beta 0.57 | 52 Weeks Range 0.58 - 8.30 | Updated Date 03/10/2025 |
52 Weeks Range 0.58 - 8.30 | Updated Date 03/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.85 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -222.49% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 23969974 | Price to Sales(TTM) 50.83 |
Enterprise Value 23969974 | Price to Sales(TTM) 50.83 | ||
Enterprise Value to Revenue 49.42 | Enterprise Value to EBITDA -1.64 | Shares Outstanding 11677900 | Shares Floating 5354862 |
Shares Outstanding 11677900 | Shares Floating 5354862 | ||
Percent Insiders 18.16 | Percent Institutions 2.46 |
Analyst Ratings
Rating 5 | Target Price 6.25 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Calidi Biotherapeutics Inc.
Company Overview
History and Background
Calidi Biotherapeutics Inc. is a clinical-stage biotechnology company focused on developing oncolytic virotherapies for cancer. Founded to harness the power of the body's immune system to fight cancer, Calidi has developed a novel platform technology for oncolytic viruses.
Core Business Areas
- Oncolytic Virotherapy Development: Calidi's core business is the development and clinical testing of oncolytic viruses designed to selectively infect and kill cancer cells while stimulating an immune response against the tumor.
- Platform Technology: Calidi develops a novel platform that aims to solve challenges regarding oncolytic virotherapy.
Leadership and Structure
Calidi Biotherapeutics is led by a management team with experience in oncology drug development. The organizational structure consists of research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- CLD-101: A tumor-selective vaccinia virus armed with human GM-CSF and an anti-PDL1 antibody. Currently in clinical trials for various solid tumors. No definitive market share data available. Competitors include companies developing other oncolytic viruses and immuno-oncology therapies such as Amgen, Merck, Bristol Myers Squibb.
- CLD-201: An allogeneic stem cell-based delivery system. Currently in clinical trials for Glioma. No definitive market share data available. Competitors include companies developing cellular therapies and immuno-oncology therapies such as Novartis, Gilead.
Market Dynamics
Industry Overview
The oncolytic virotherapy market is growing, driven by advancements in immunotherapy and gene therapy. Oncolytic viruses are seen as a promising approach to treat cancer with fewer side effects than traditional treatments.
Positioning
Calidi Biotherapeutics is a clinical-stage company focused on oncolytic virotherapy. Its competitive advantage lies in its novel platform and approach to develop innovative therapies for cancer.
Total Addressable Market (TAM)
The global oncolytic virus therapy market is projected to reach billions of dollars. Calidi Biotherapeutics aims to capture a significant portion of this market through the successful development and commercialization of its oncolytic virotherapies.
Upturn SWOT Analysis
Strengths
- Novel oncolytic virotherapy platform
- Potential for combination therapies
- Experienced management team
- Proprietary technology
Weaknesses
- Clinical-stage company with no approved products
- Reliance on clinical trial results
- Limited financial resources
- High competition in the biotechnology sector
Opportunities
- Successful clinical trial outcomes
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Advancements in manufacturing technology
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Changes in the healthcare landscape
Competitors and Market Share
Key Competitors
- AMGN
- MRK
- BMY
Competitive Landscape
Calidi Biotherapeutics faces competition from established pharmaceutical companies. Its advantage lies in its novel platform and approach to develop innovative therapies for cancer. The company's proprietary technology differentiates it.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Calidi Biotherapeutics is a clinical-stage company and has not yet generated revenues from product sales.
Future Projections: Future growth depends on the successful development and commercialization of its oncolytic virotherapies.
Recent Initiatives: Focus on advancing clinical trials of CLD-101 and CLD-201.
Summary
Calidi Biotherapeutics is a clinical-stage company with a novel oncolytic virotherapy platform and is currently loss making with no approved products. Success hinges on positive clinical trial outcomes and securing partnerships. Competition from larger, established pharmaceutical companies poses a risk, requiring careful financial management and strategic execution of partnerships.
Similar Companies
- AMGN
- MRK
- BMY
- NK
- CRIS
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. The analysis is based on publicly available information and may be subject to change. Market share is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Calidi Biotherapeutics Inc.
Exchange NYSE MKT | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-11-01 | CEO & Chairman of the Board Mr. Allan J. Camaisa | ||
Sector Healthcare | Industry Biotechnology | Full time employees 41 | Website https://www.calidibio.com |
Full time employees 41 | Website https://www.calidibio.com | ||
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.